GGrantIndex
← Leaderboards

Udo Hoffmann

Massachusetts General Hospital

$17,171,978
Attributed
$22,168,632
Total exposure
9
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.4M · FY200620
$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$22,168,632 · 9

By mechanism

U01$10,067,481 · 2
R01$6,480,009 · 3
T32$2,329,440 · 1
R33$1,437,929 · 1
K24$1,123,870 · 1
R61$729,903 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Cardiac

Research focus

CardiacImageRandomizedCoronaryChest PainCoronary ArteriosclerosisEventUnited States National Institutes Of HealthIndexingDiagnosticBaseAcuteAngiographyDiagnostic TestsHospitalizationResearch PersonnelProgramsRisk FactorsGrantFundingLeadershipCost EffectivenessMyocardial IschemiaCost

Grant awards (37)

Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$721,297
R33 · FY2020 · HL
Cardiovascular Imaging in Ischemic Heart Disease$120,852
K24 · FY2020 · HL · contact PI
Clinical and Molecular Epidemiology of High Risk Coronary Plaque$1,485,906
R01 · FY2019 · HL
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$716,632
R33 · FY2019 · HL
Cardiovascular Imaging in Ischemic Heart Disease$120,852
K24 · FY2019 · HL · contact PI
REPRIEVE - DCC$926,776
U01 · FY2018 · HL · contact PI
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$729,903
R61 · FY2018 · HL
Cardiac MR and CT Research$297,033
T32 · FY2018 · HL · contact PI
Cardiovascular Imaging in Ischemic Heart Disease$120,852
K24 · FY2018 · HL · contact PI
REPRIEVE - DCC$906,151
U01 · FY2017 · HL · contact PI
Cardiac MR and CT Research$380,168
T32 · FY2017 · HL · contact PI
Cardiovascular Imaging in Ischemic Heart Disease$121,969
K24 · FY2017 · HL · contact PI
REPRIEVE - DCC$957,177
U01 · FY2016 · HL · contact PI
Cardiac MR and CT Research$257,488
T32 · FY2016 · HL · contact PI
Cardiovascular Imaging in Ischemic Heart Disease$127,869
K24 · FY2016 · HL · contact PI
REPRIEVE - DCC$972,448
U01 · FY2015 · HL · contact PI
Cardiac MR and CT Research$362,262
T32 · FY2015 · HL · contact PI
Cardiovascular Imaging in Ischemic Heart Disease$127,869
K24 · FY2015 · HL · contact PI
REPRIEVE - DCC$1,359,105
U01 · FY2014 · HL · contact PI
Cardiovascular Imaging in Ischemic Heart Disease$127,869
K24 · FY2014 · HL · contact PI
PROMISE Trial: Dx Core$43,426
R01 · FY2014 · HL · contact PI
Cardiac MR and CT Research$359,410
T32 · FY2013 · HL · contact PI
ROMICAT II - CCC - Lead Application$258,476
U01 · FY2013 · HL · contact PI
Cardiovascular Imaging in Ischemic Heart Disease$127,869
K24 · FY2013 · HL · contact PI
PROMISE Trial: Dx Core$42,058
R01 · FY2013 · HL · contact PI
ROMICAT II - CCC - Lead Application$1,045,138
U01 · FY2012 · HL · contact PI
PROMISE Trial: Dx Core$595,030
R01 · FY2012 · HL · contact PI
Cardiac MR and CT Research$340,962
T32 · FY2012 · HL · contact PI
Cardiovascular Imaging in Ischemic Heart Disease$127,869
K24 · FY2012 · HL · contact PI
Cardiac MR and CT Research$332,117
T32 · FY2011 · HL · contact PI
ROMICAT II - CCC - Lead Application$1,913,403
U01 · FY2010 · HL · contact PI
PROMISE Trial: Dx Core$1,104,840
R01 · FY2010 · HL · contact PI
ROMICAT II - CCC - Lead Application$1,728,807
U01 · FY2009 · HL · contact PI
PROMISE Trial: Dx Core$1,697,082
R01 · FY2009 · HL · contact PI
Cardiac MDCT for Early Triage of Patients with ACS$522,822
R01 · FY2008 · HL · contact PI
Cardiac MDCT for Early Triage of Patients with ACS$526,873
R01 · FY2007 · HL · contact PI
Cardiac MDCT for Early Triage of Patients with ACS$461,972
R01 · FY2006 · HL · contact PI